Sigyn Therapeutics, Inc. (SIGY)
USD 4.15
(0.0%)
USD 4.15
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -4.14 Million USD | -11.69% |
| 2022 | -3.71 Million USD | -9.06% |
| 2021 | -3.4 Million USD | -112.37% |
| 2020 | -1.6 Million USD | 48.79% |
| 2019 | -3.12 Million USD | -19.45% |
| 2018 | -2.62 Million USD | 38.36% |
| 2017 | -4.25 Million USD | -411.26% |
| 2016 | -831.53 Thousand USD | 69.14% |
| 2015 | -2.69 Million USD | -595.23% |
| 2014 | -387.54 Thousand USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -758.08 Thousand USD | 35.54% |
| 2024 Q2 | -862.38 Thousand USD | -13.76% |
| 2023 Q2 | -723.12 Thousand USD | 66.52% |
| 2023 Q1 | -2.15 Million USD | -35.26% |
| 2023 FY | -4.14 Million USD | -11.69% |
| 2023 Q4 | -1.17 Million USD | -29.85% |
| 2023 Q3 | -905.72 Thousand USD | -25.25% |
| 2022 Q3 | -919.37 Thousand USD | -14.94% |
| 2022 Q4 | -1.59 Million USD | -73.67% |
| 2022 FY | -3.71 Million USD | -9.06% |
| 2022 Q1 | -746.85 Thousand USD | 39.14% |
| 2022 Q2 | -799.85 Thousand USD | -7.1% |
| 2021 FY | -3.4 Million USD | -112.37% |
| 2021 Q3 | -665.9 Thousand USD | -2.47% |
| 2021 Q1 | -461.68 Thousand USD | 45.05% |
| 2021 Q2 | -649.86 Thousand USD | -40.76% |
| 2021 Q4 | -1.22 Million USD | -84.29% |
| 2020 FY | -1.6 Million USD | 48.79% |
| 2020 Q1 | -153.21 Thousand USD | 94.67% |
| 2020 Q3 | -150.54 Thousand USD | -30.17% |
| 2020 Q2 | -115.65 Thousand USD | 24.51% |
| 2020 Q4 | -840.17 Thousand USD | -458.09% |
| 2019 Q2 | -116.81 Thousand USD | -316.49% |
| 2019 Q1 | 53.96 Thousand USD | 104.43% |
| 2019 FY | -3.12 Million USD | -19.45% |
| 2019 Q4 | -2.87 Million USD | -1973.43% |
| 2019 Q3 | -138.57 Thousand USD | -18.63% |
| 2018 Q3 | -355.98 Thousand USD | -15.85% |
| 2018 Q4 | -1.21 Million USD | -242.03% |
| 2018 Q1 | -739.39 Thousand USD | 37.09% |
| 2018 Q2 | -307.27 Thousand USD | 58.44% |
| 2018 FY | -2.62 Million USD | 38.36% |
| 2017 Q2 | -967.48 Thousand USD | -57.6% |
| 2017 FY | -4.25 Million USD | -411.26% |
| 2017 Q4 | -1.17 Million USD | 21.53% |
| 2017 Q3 | -1.49 Million USD | -54.8% |
| 2017 Q1 | -613.89 Thousand USD | -144.85% |
| 2016 Q4 | 1.36 Million USD | 416.49% |
| 2016 Q3 | -432.52 Thousand USD | 51.17% |
| 2016 Q1 | -851.24 Thousand USD | 32.07% |
| 2016 Q2 | -885.7 Thousand USD | -4.05% |
| 2016 FY | -831.53 Thousand USD | 69.14% |
| 2015 Q1 | -151.79 Thousand USD | -7.89% |
| 2015 Q4 | -1.25 Million USD | -53.47% |
| 2015 FY | -2.69 Million USD | -595.23% |
| 2015 Q3 | -816.55 Thousand USD | -68.97% |
| 2015 Q2 | -483.26 Thousand USD | -218.36% |
| 2014 Q3 | -78.32 Thousand USD | 0.0% |
| 2014 FY | -387.54 Thousand USD | 0.0% |
| 2014 Q4 | -140.7 Thousand USD | -79.63% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1.33 Million USD | -210.457% |
| Arch Therapeutics, Inc. | -6.98 Million USD | 40.627% |
| Evofem Biosciences, Inc. | 52.97 Million USD | 107.826% |
| Nascent Biotech, Inc. | -2.08 Million USD | -98.59% |
| Rebus Holdings, Inc. | -1.02 Million USD | -306.464% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 106.365% |
| Qrons Inc. | -789.34 Thousand USD | -425.236% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -555.58% |
| Adynxx, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 93.377% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -897.869% |
| Skye Bioscience, Inc. | -37.64 Million USD | 88.987% |
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 94.469% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | 36.955% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | -1416.425% |
| SQZ Biotechnologies Company | -79.46 Million USD | 94.783% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | -43.339% |
| Propanc Biopharma, Inc. | -1.82 Million USD | -127.733% |
| Mesoblast Limited | -87.95 Million USD | 95.286% |
| Marizyme, Inc. | -65.34 Million USD | 93.655% |
| Genus plc | 7.9 Million USD | 152.48% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | 61.935% |
| Pharming Group N.V. | -10.54 Million USD | 60.695% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | -91.073% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | -11.743% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | 53.121% |
| ContraFect Corporation | -65.15 Million USD | 93.637% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | 15.148% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | -140.003% |
| IMV Inc. | -36.48 Million USD | 88.637% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | 48.56% |
| MultiCell Technologies, Inc. | -380.07 USD | -1090734.846% |
| ONE Bio Corp. | 8.67 Million USD | 147.783% |
| Accustem Sciences Inc. | -3.74 Million USD | -10.664% |
| RVL Pharmaceuticals plc | -51.69 Million USD | 91.98% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -1.26 Million USD | -227.19% |
| Q BioMed Inc. | -2.05 Million USD | -102.035% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | -11.062% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | -74.135% |
| Biomind Labs Inc. | -1.21 Million USD | -241.421% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | 93.058% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | -33.664% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | 47.54% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | -112.694% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | -27583.868% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | 73.878% |
| Curative Biotechnology, Inc. | -5.81 Million USD | 28.73% |
| GB Sciences, Inc. | -1.36 Million USD | -204.473% |
| Alpha Cognition Inc. | -13.77 Million USD | 69.897% |
| HST Global, Inc. | -146.21 Thousand USD | -2735.604% |
| CSL Limited | 2.64 Billion USD | 100.157% |
| Wesana Health Holdings Inc. | -1.75 Million USD | -136.266% |
| Halberd Corporation | -79.67 Thousand USD | -5103.494% |
| Enzolytics Inc. | -2.17 Million USD | -90.457% |
| Agentix Corp. | -1.37 Million USD | -201.696% |
| Resverlogix Corp. | -3.61 Million USD | -14.846% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | -30.727% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -295.05 Million USD | 98.595% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | 4330.547% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | 159.873% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | -4.353% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | -37.004% |
| AVAX Technologies, Inc. | -6.41 Million USD | 35.358% |
| Zenith Capital Corp. | -10.59 Million USD | 60.873% |
| Genscript Biotech Corporation | -95.47 Million USD | 95.658% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | -17738.121% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | -6759.52% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -106.768% |
| Kadimastem Ltd | -3.3 Million USD | -25.353% |
| Helix BioMedix, Inc. | -1.05 Million USD | -292.586% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -3.81 Million USD | -8.561% |
| BioStem Technologies, Inc. | -8.48 Million USD | 51.126% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -441.36 Thousand USD | -839.336% |
| LadRx Corporation | 400.44 Thousand USD | 1135.337% |
| Cell Source, Inc. | -5.32 Million USD | 22.087% |
| Regen BioPharma, Inc. | 1.02 Million USD | 505.071% |
| Regen BioPharma, Inc. | 1.02 Million USD | 505.071% |
| NovAccess Global Inc. | -4.76 Million USD | 13.068% |
| Affymax, Inc. | -14.42 Million USD | 71.257% |
| Itoco Inc. | -1.86 Million USD | -121.827% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | 6.676% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | -148.408% |
| Mobile Lads Corp. | -2.26 Million USD | -83.182% |
| CytoDyn Inc. | -49.84 Million USD | 91.682% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | -5145.829% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | -1717.381% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | -340.341% |
| SYBLEU INC | -180.3 Thousand USD | -2199.414% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | -157.075% |
| International Stem Cell Corporation | -131 Thousand USD | -3064.837% |
| Bioxytran, Inc. | -4.28 Million USD | 3.132% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | -7539.18% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | -63.855% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -48.07 Million USD | 91.376% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | -96.118% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -780.88 Thousand USD | -430.926% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | -30.869% |
| Neutra Corp. | -233.46 Thousand USD | -1675.828% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 79.568% |
| PureTech Health plc | -65.69 Million USD | 93.689% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | 80.505% |
| IXICO plc | -1.17 Million USD | -251.947% |
| IntelGenx Technologies Corp. | -9.92 Million USD | 58.236% |
| Gelesis Holdings, Inc. | -57.12 Million USD | 92.743% |
| CSL Limited | 2.64 Billion USD | 100.157% |
| Cellectis S.A. | -103.17 Million USD | 95.982% |